eMed Chief Medical Officer Tom Brady and eMed CEO Linda Yaccarino discuss the growth of the GLP-1 market and the company’s latest funding round on ‘Mornings with Maria.’
As the market for GLP-1 weight loss drugs explodes to an estimated $150 billion, NFL legend Tom Brady enters the arena – not to promote a magic pill, but to introduce clinical surgery with his trademark “TB12” regimen.
“I’m making a difference in other people’s lives, I’m trying to share some of the things that were in my mind that I’ve learned from amazing mentors, understanding and trying to encourage different people who have come into my life to pass on the messages that I’ve been able to get, that have helped me to live my dream, and I want to do that to others,” said Brady in an exclusive interview with Maria.
Seven-time Super Bowl champion and eMed CEO Linda Yaccarino have teamed up to announce a massive $200 million funding round, valuing the digital health company at more than $2 billion. The duo aims to transform “people’s health” by using AI and clinical oversight to provide employers with a sustainable way to supply GLP-1 weight loss drugs like Ozempic and Mounjaro, while reducing the company’s insurance claims.
“The promotion ensures great momentum and establishes us as a definitive company in the health of people and helps employers to break the cost of health care and break their cost curve,” Yaccarino told Bartiromo.
TOM BRADY SAYS POST-NFL LIFE IS ABOUT ‘BUILDING TRUST’ AS HE DOES BUSINESS WITH HERTZ
“If you have people who are overweight or obese, their health care costs are twice as high as the average worker who is not overweight,” he continued. “So that’s the unanswered question, that ultimately, eMed comes in, is able to bring those solutions to employers across the country.”
Tom Brady at the Fanatics Flag Football Classic Press Conference & Practice at BMO Stadium on March 20, 2026, in Los Angeles, California. (Getty Images)
While many Americans use GLP-1s as a simple solution to weight loss, Brady views the eMed platform as a starting point for those who do not have the benefit of natural high-potency biologics. He insists that medicine should be based on a foundation of clinical support and personal accountability.
“This isn’t about shortcuts for anyone. This is about a well-delivered program for people to start their health journey in some ways,” Brady explained. “I was lucky enough to be around the best experts, the best doctors, the best trainers, the best nutritionists. And I realized how lucky I was to have that guidance.”
“I really want to break the stigma about the fact that, you know, discipline and hard work and strength is something that is … born with. I was born with that, and I have the ability to do that. I think there are a lot of other people that that’s a very difficult thing,” he added. “But we need to be able to support those people.”
Seven-time Super Bowl champion Tom Brady and Aescape CEO Eric Litman discuss the NFL star’s relationship with next-generation AI massage technology on ‘The Claman Countdown.’
Brady went on to explain that his most valuable asset requires a level of care that has become routine.
“I realized because I was an athlete, my body was my treasure,” said the former midfielder. “If I like to play football and I like to be on the field, then I like to do my best. I had to treat my body, you know, in a very specific way. I tried to get a lot of muscle work to repair the injured muscles. I was always hydrated. I tried to eat a low-inflammatory diet. I tried to get proper rest.”
“How can I ever stop? This is my life, I’m telling you, I’ve always been very focused on training. I would feel terrible and worse if I didn’t move all the time. I feel like I have a lot of energy … I want to stay active. I have three children. I want to get out there and play basketball and swim and hit the golf ball, and play volleyball with my daughter in the backyard,” said Brady in the backyard.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
Novo Nordisk President and CEO Mike Doustdar joins ‘Mornings with Maria’ to discuss the launch of the first GLP-1 weight loss pill in the US, the lawsuit against Hims & Hers and talks with the Trump administration about drug pricing.
Yaccarino — the former CEO of X Corp who declined to comment on Wednesday’s decision on social media — explained that EMed’s goal is to take Brady’s “strength” and apply it to the American workforce and reduce chronic disease.
“Ninety percent of people stay on our program. They do two things: First, and most importantly, what Tom was referring to, they get healthy,” he said. “And when you get people in the system, when you deliver those health outcomes, that’s the secret sauce for employers, for CEOs, CFOs — you have them on your show all the time — because they’re getting their return on their investment.”
READ MORE AT FOX BUSINESS
